Triptorelin acetate

ApprovedSmall molecule

Ipsen

Triptorelin acetate is one of 133 small molecule programs targeting Adenomyosis. It is currently in Approved.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Polycystic Ovary SyndromeActive, not recruiting

EndometriosisActive, not recruiting

AdenomyosisPhase 1

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Polycystic Ovary SyndromeApproved

Active, not recruiting

EndometriosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

269 competitors in Metastatic Prostate Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

18 2

Taxotere

AAvyxa

Phase 3

43 3

Erleada

Johnson & Johnson

Phase 3

15 4

Nubeqa

Bayer

Phase 3

7 5

Jevtana

Sanofi

Phase 3

7 6

Zoladex

AstraZeneca

Phase 3

7 7

Rayos

RRoxane Laboratories

Phase 3

20 8

Zometa

Pfizer

Phase 3

4 9

Prolia

Amgen

Phase 3

2 10

Medrol

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GnRH Antagonist3 trials

Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

Terminated·VV.K.V. American Hospital, Istanbul·Phase 3·NCT01007851

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

Completed·—·Phase 4·NCT04724343·50 enrolled

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

Completed·—·Phase 4·NCT04724486·50 enrolled

Endometriosis2 trials

The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis

Completed·IInstituto de Investigacion Sanitaria La Fe·Phase 4·NCT01581359·200 enrolled

A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

Completed· Ipsen logo

Ipsen··NCT01942369·402 enrolled

Polycystic Ovary Syndrome2 trials

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

Completed·—·Phase 4·NCT04727684·50 enrolled

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

Completed·—·Phase 4·NCT04727671·50 enrolled

CLE1 trial

GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

Completed·VV.K.V. American Hospital, Istanbul·N/A·NCT00516490·570 enrolled

Metastatic Prostate Cancer1 trial

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Unknown status·FFudan University·Phase 2·NCT05212857·160 enrolled

5 more indications

Ovarian Hyperstimulation1 trial

The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation

Unknown status·PPeking University People's Hospital·Phase 4·NCT03809221·1,892 enrolled

Embryo Transfer1 trial

Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study

Unknown status·SSheba Medical Center·Phase 4·NCT02825290·62 enrolled

Adenomyosis1 trial

Long-term Use of Mifepristone in the Treatment of Adenomyosis

Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·Phase 1·NCT05151016·140 enrolled

Steroid1 trial

Effects of Sex Steroids on the Serotonin System

Unknown status·MMedical University of Vienna·Phase 4·NCT02715232·92 enrolled

Ovarian Stimulation1 trial

Comparison of Triggers in Double Ovarian Stimulation (DuoStim).

Unknown status·IInstituto Bernabeu·Phase 4·NCT05321511·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Triptorelin acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triptorelin acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triptorelin acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Ipsen

Triptorelin acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GnRH Antagonist3 trials

Endometriosis2 trials

Polycystic Ovary Syndrome2 trials

CLE1 trial

Metastatic Prostate Cancer1 trial

Ovarian Hyperstimulation1 trial

Embryo Transfer1 trial

Adenomyosis1 trial

Steroid1 trial

Ovarian Stimulation1 trial

References

Drug Info

Quick Facts

Related News